Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 28

References for PMC Articles for PubMed (Select 16439435)

1.

Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis.

Genovese MC, Bathon JM, Fleischmann RM, Moreland LW, Martin RW, Whitmore JB, Tsuji WH, Leff JA.

J Rheumatol. 2005 Jul;32(7):1232-42.

PMID:
15996057
2.

Safety of biologic therapies--an update.

Keystone EC.

J Rheumatol Suppl. 2005 Mar;74:8-12. Review.

PMID:
15742458
3.

Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2004 Aug 6;53(30):683-6.

5.
7.

Rheumatoid arthritis and malignant lymphomas.

Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog L.

Curr Opin Rheumatol. 2004 May;16(3):254-61. Review.

PMID:
15103253
8.

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.

van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, Settas L, Bijlsma JW, Todesco S, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischkoff S, Kupper H.

Ann Rheum Dis. 2004 May;63(5):508-16.

9.

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.

Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, St Clair EW, Keenan GF, van der Heijde D, Marsters PA, Lipsky PE; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Arthritis Rheum. 2004 Apr;50(4):1051-65.

10.
11.
12.

Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy.

Kroesen S, Widmer AF, Tyndall A, Hasler P.

Rheumatology (Oxford). 2003 May;42(5):617-21.

13.

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.

Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh DC.

Lancet Infect Dis. 2003 Mar;3(3):148-55. Review.

PMID:
12614731
14.

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK.

Arthritis Rheum. 2003 Jan;48(1):35-45. Erratum in: Arthritis Rheum. 2003 Mar;48(3):855.

15.

Predictors of infection in rheumatoid arthritis.

Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE.

Arthritis Rheum. 2002 Sep;46(9):2294-300.

16.

Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study.

Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE.

Arthritis Rheum. 2002 Sep;46(9):2287-93.

17.

Examining the efficacy of biologic therapy: are there real differences?

Fleischmann RM.

J Rheumatol Suppl. 2002 Sep;65:27-32. Review.

PMID:
12236619
18.

Experience with etanercept in an academic medical center: are infection rates increased?

Phillips K, Husni ME, Karlson EW, Coblyn JS.

Arthritis Rheum. 2002 Feb;47(1):17-21.

PMID:
11932873
19.

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN.

Arthritis Rheum. 2001 Dec;44(12):2862-9.

PMID:
11762947
20.

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

N Engl J Med. 2000 Nov 30;343(22):1594-602.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk